Genomic Governance Ensures Equity at the Core of Drug Discovery

The expansion of global genomics infrastructure is reshaping drug discovery and clinical R&D. Yet, as sequencing platforms, biobanks, and AI‑driven analytics scale, the question is not only how much data we generate, but whose genomic data defines the future of clinical tools and pharma innovation.

Image

Why Equitable Genomic Governance Matters for Pharma R&D

Drug discovery increasingly depends on genomic insights.

Rare disease R&D pipelines, oncology biomarkers, and pharmacogenomics programmes all rely on large‑scale datasets to identify therapeutic targets and stratify patient populations.

However, most global datasets remain disproportionately weighted toward individuals of European ancestry.

This imbalance undermines predictive accuracy, limits therapeutic relevance, and risks embedding inequity into AI‑enabled diagnostic systems.

For pharmaceutical R&D leaders, genomic governance now directly influences the research validity of discovery platforms, the reproducibility of translational research, and the credibility of clinical tools in diverse patient populations.

As a result, the U.S. Food and Drug Administration’s regulatory posture and the World Health Organization’s guidance on genome data governance converge on a critical point: Without inclusive frameworks, biased datasets risk becoming entrenched in the very foundations of precision medicine.

Image

How Biased Genomic Datasets Limit AI and Precision Medicine

Artificial intelligence has accelerated almost every stage of pharmaceutical research.

Machine learning models identify therapeutic targets, predict protein structures, classify pathogenic variants, optimise clinical trial recruitment, and increasingly support clinical decision-making.

Foundation models trained on genomic information are now capable of analysing biological relationships that would have been impossible only a few years ago.

However, AI does not remove bias from genomic research.

It learns from it.

Researchers warn that biased genomic datasets create a “biased baseline” that becomes progressively more difficult to correct as AI systems mature.

Algorithms trained on incomplete genomic information inevitably produce less reliable predictions for underrepresented populations, increasing the risk of inaccurate variant classification, weaker disease prediction models, and unequal treatment recommendations.

The risks of biased genomic datasets extend well beyond clinical diagnostics, and include:

• Target identification algorithms may fail to recognise population-specific biological pathways.
• Predictive biomarkers may perform well during development but lose accuracy when therapies enter broader global markets.
• Polygenic risk scores may provide clinically useful insights for one population while performing substantially worse for another.

Even AI-supported patient stratification within clinical trials can become less reliable if the underlying genomic evidence fails to reflect the intended treatment population.

Rather than reducing uncertainty, biased datasets risk transferring existing knowledge gaps into increasingly sophisticated computational systems.

This is particularly significant because AI is now being integrated throughout the discovery pipeline:

• Large language models support scientific reasoning.
• Generative AI tools design novel compounds.
• Machine learning identifies therapeutic targets.
• Multi-modal foundation models combine genomic, imaging, and clinical data to improve biological understanding.

Each technological advance increases the value of representative genomic data.

Consequently, genomic equity should not be viewed as a separate initiative alongside AI adoption.

Therefore, equitable genomic data systems is one of the foundational requirements for building reliable AI-enabled pharmaceutical research.

Image

Equity is Essential for Truly Innovative Pharma R&D

The window of opportunity for creating an equitable global genomic system may be narrowing.

If biased genomic data baselines are allowed to persist, they will cascade into every downstream application, all the way from variant classification through risk prediction.

Correcting this requires deliberate equitable genomic governance models that embed equity, diversity, and representation into genomic systems by design.

This translates into three core factors for pharma:

• Invest in diverse datasets: Expand recruitment beyond high‑income geographies to ensure therapeutic relevance across populations.
• Adopt community-centred consent frameworks: Move beyond extractive models toward participatory governance that reflects local priorities.
• Integrate equity indicators into R&D metrics: Representation ratios, intersectionality scores, and benefit‑sharing timelines should become part of portfolio evaluation.

Aligning Innovation with Equitable Genomic Regulation

Global regulators are beginning to formalise equitable genomic data expectations.

The WHO’s 2024 guidance on genome data collection emphasises solidarity, transparency, and accountability, while the FDA’s evolving stance on advanced manufacturing and data oversight reflects a similar recognition that governance must keep pace with innovation.

For pharma R&D, this alignment creates both risk and opportunity. Companies that embed equity into genomic discovery pipelines will be better positioned to meet regulatory expectations, secure public trust, and accelerate adoption of AI‑driven clinical tools.

Those that fail to ensure equitable genomic data systems may find their platforms challenged on both scientific and ethical grounds.

Building Inclusive and Equitable Genomic Systems

Practical models to develop equitable genomic data systems are emerging.

African‑led initiatives such as H3Africa demonstrate the value of community engagement and regional leadership.

Federated data‑access systems, like the European Genome‑phenome Archive (EGA), show how interoperability can balance privacy with collaboration

Indigenous governance frameworks, including the CARE and Canada’s First Nation’s OCAP principles, highlight the importance of sovereignty and reciprocity in data use.

Pharma R&D leaders should use the strategy of these models to embed pluralistic governance into discovery platforms, ensuring that innovation is as socially legitimate as it is technically advanced.

Image

Genomic Equity as Innovation for Pharma

The future of drug discovery needs more than scientific breakthroughs, and will depend on whether genomic systems advance equity or entrench disparities.

R&D portfolio teams should aim to integrate governance for genomic equity into strategy, treat equity as a measurable precondition for innovation, and align discovery pipelines with global regulatory expectations.

At Pharmatica, we analyse how governance, equity, and innovation intersect to shape the next era of drug discovery. By embedding inclusive genomic systems into R&D, pharma leaders can ensure that clinical tools deliver both scientific excellence and societal value.

Pharmatica: Insight. Connection. Impact.